Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study

INTRODUCTION: Lenvatinib plus an anti-PD-1 antibody has shown promising antitumor effects in patients with advanced hepatocellular carcinoma (HCC), but with clinical benefit limited to a subset of patients. We developed and validated a radiomic-based model to predict objective response to this combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Bin, Dong, San-Yuan, Bai, Xue-Li, Song, Tian-Qiang, Zhang, Bo-Heng, Zhou, Le-Du, Chen, Yong-Jun, Zeng, Zhi-Ming, Wang, Kui, Zhao, Hai-Tao, Lu, Na, Zhang, Wei, Li, Xu-Bin, Zheng, Su-Su, Long, Guo, Yang, Yu-Chen, Huang, Hua-Sheng, Huang, Lan-Qing, Wang, Yun-Chao, Liang, Fei, Zhu, Xiao-Dong, Huang, Cheng, Shen, Ying-Hao, Zhou, Jian, Zeng, Meng-Su, Fan, Jia, Rao, Sheng-Xiang, Sun, Hui-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433098/
https://www.ncbi.nlm.nih.gov/pubmed/37601982
http://dx.doi.org/10.1159/000528034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433098/
https://www.ncbi.nlm.nih.gov/pubmed/37601982
http://dx.doi.org/10.1159/000528034

Ejemplares similares